Science Explorer Back to mapMap
Discussion

COVID-19 Clinical Research Studies

COVID-19 Clinical Research Studies is a research topic within Infectious Diseases. Science Explorer counts 51k research works in it since 1950. 9.6% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the clinical characteristics, epidemiology, immune response, and treatment of Coronavirus Disease 2019 (COVID-19), caused by the SARS-CoV-2 virus. It covers topics such as thrombosis, ACE2 receptor, cytokine storm, and the pandemic's impact on various populations.

  • Clinical Characteristics
  • SARS-CoV-2
  • Epidemiology
  • Thrombosis
  • Immune Response
  • ACE2 Receptor
  • Cytokine Storm
  • Antiviral Treatment
  • Pathophysiology
  • Pandemic
Research works
51k
fractional, since 1950
In the world top 10%
4.9k
per year above
Top-10% rate
9.6%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-3%
the tick is no change
Largest producer
United States
29% of the 10 largest, 2022-now
COVID-19 Clinical Research Studies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead COVID-19 Clinical Research Studies research?

By volume, the United States and China publish the most (4.2k and 2.1k works in 2022-now).

By volume, 2022-now

  1. 1 United States 4.2k works
  2. 2 China 2.1k works
  3. 3 India 1.8k works
  4. 4 Italy 1.1k works
  5. 5 Iran 914 works
  6. 6 United Kingdom 895 works
  7. 7 Brazil 892 works
  8. 8 Türkiye 876 works
  9. 9 Spain 796 works
  10. 10 Japan 692 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 29.5%China: 14.5%India: 12.9%Italy: 7.5%6 others listed: 35.7%29%largest
United States4,175 · 29.5%China2,051 · 14.5%India1,824 · 12.9%Italy1,058 · 7.5%6 others listed5,065 · 35.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead COVID-19 Clinical Research Studies research?

By volume in 2022-now, Harvard University publishes the most COVID-19 Clinical Research Studies research, followed by All India Institute of Medical Sciences and University of North Carolina at Chapel Hill.

Who are the leading researchers in COVID-19 Clinical Research Studies?

The most-cited researchers publishing on COVID-19 Clinical Research Studies include David Moher, Christopher J L Murray and Freddie Bray.

  1. 1 David Moher Canada 898k citations
  2. 2 Christopher J L Murray United States 583k citations
  3. 3 Freddie Bray France 550k citations
  4. 4 Zhong Lin Wang United States 491k citations
  5. 5 Rob Knight United States 468k citations
  6. 6 Simon Iain Hay United States 452k citations
  7. 7 Theo Vos United States 439k citations
  8. 8 George Davey Smith United Kingdom 435k citations
  9. 9 Ali H. Mokdad United States 429k citations
  10. 10 Mark J. Daly United States 403k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in COVID-19 Clinical Research Studies?

The most cited paper in COVID-19 Clinical Research Studies is "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" (Chaolin Huang et al., 2020), with 52,028 citations. Next come "Clinical Characteristics of Coronavirus Disease 2019 in China" (31,256) and "A Novel Coronavirus from Patients with Pneumonia in China, 2019" (30,499).

Most cited papers
#PaperReleasedCitations
1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Chaolin Huang et al. · The Lancet Open access 24 Jan 2020 52,028
2 Clinical Characteristics of Coronavirus Disease 2019 in China Wei‐jie Guan et al. · New England Journal of Medicine Open access 28 Feb 2020 31,256
3 A Novel Coronavirus from Patients with Pneumonia in China, 2019 Na Zhu, Dingyu Zhang, Wenling Wang et al. · New England Journal of Medicine Open access 24 Jan 2020 30,499
4 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Fei Zhou, Ting Yu, Ronghui Du et al. · The Lancet Open access Mar 2020 29,236
5 A pneumonia outbreak associated with a new coronavirus of probable bat origin Peng Zhou et al. · Nature Open access 3 Feb 2020 23,429
All 98 most cited papers, with filters and sorting

Where is COVID-19 Clinical Research Studies research done?

The largest centres of COVID-19 Clinical Research Studies research in 2022-now are Tehran (Iran), Beijing (China), London (United Kingdom) and Moscow (Russia).

Largest cities, 2022-now

  1. 1 TehranIran 347 works
  2. 2 BeijingChina 345 works
  3. 3 LondonUnited Kingdom 319 works
  4. 4 MoscowRussia 281 works
  5. 5 IstanbulTürkiye 271 works
  6. 6 MadridSpain 245 works
  7. 7 New YorkUnited States 243 works
  8. 8 TokyoJapan 217 works
  9. 9 São PauloBrazil 215 works
  10. 10 RomeItaly 210 works
See COVID-19 Clinical Research Studies on the map

Where is the best place to study COVID-19 Clinical Research Studies?

Among universities, judged by research, University of Hong Kong, Harvard University and Karolinska Institutet score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 21.19%fractional works in this field (log) →share of work in the world top 10% →London School of Hyg…University of Hong K…Harvard UniversityKarolinska Institutet
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1University of Hong KongChina 78.622.8%2.6×51 +16.5%
2Harvard UniversityUnited States 74.721.6%2.4×158 -28.0%
3Karolinska InstitutetSweden 68.318.9%4.3×51 +8.7%
4London School of Hygiene & Tropical MedicineUnited Kingdom 67.123.0%6.0×20 -0.1%
5University of OxfordUnited Kingdom 63.423.1%1.8×52 -24.4%
6University of CopenhagenDenmark 63.220.0%1.6×32 +26.8%
7Johns Hopkins UniversityUnited States 62.817.4%2.8×88 -12.9%
8Imperial College LondonUnited Kingdom 62.723.1%2.0×42 -31.9%
9Erasmus University RotterdamNetherlands 62.720.5%2.3×25 +11.2%
10Chinese University of Hong KongChina 62.421.5%1.7×26 +9.8%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in COVID-19 Clinical Research Studies, country by country

Is COVID-19 Clinical Research Studies research growing?

Output in 2022-2025 was 3% lower than in 2018-2021, peaking in 2021.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is COVID-19 Clinical Research Studies as a percentage of every work published that year, 0.076% in 2024.

still counting0.10%0.20%0.30%COVID-19 Clinical Research Studies0.047% in 202519801990200020102020

Fractional works of COVID-19 Clinical Research Studies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%COVID-19 Clinical Research Studies10.0% in 20252020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Questions people ask

How much research is there on long COVID and COVID-19, and is it growing?

Output in 2022-2025 was 3% lower than in 2018-2021, peaking in 2021.

Is COVID-19 Clinical Research Studies research growing?
All 1,273 questions in the Question Catalogue

Discussion

Ask a question or share a note about COVID-19 Clinical Research Studies. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.